Ikena Oncology, Inc.
NASDAQ:IKNA
Overview | Financials
Company Name | Ikena Oncology, Inc. |
Symbol | IKNA |
Currency | USD |
Price | 1.51 |
Market Cap | 60,790,184 |
Dividend Yield | 0% |
52-week-range | 1.22 - 1.94 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark Manfredi Ph.D. |
Website | https://ikenaoncology.com |
An error occurred while fetching data.
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD